​Vertex sales prediction for top-selling drug lower than hoped

In a highly anticipated announcement today in San Francisco, executives from Vertex Pharmaceuticals told investors they expect $1.1 billion to $1.3 billion in sales of the cystic fibrosis drug Orkambi this year, falling short of most expectations. Boston-based Vertex (Nasdaq: VRTX) made the announcement at the J.P. Morgan Healthcare Conference Sunday afternoon, one of the first of what will likely be several big announcements from local biotech companies over the next several days. The 2017 guidance…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news